Choose a Year - 2004 Grant Recipients

2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004


2004 Research Fellow Award

Nicole Aqui, MD
University of Pennsylvania
"Immune assessment after autotransplantation followed by adoptive transfer of ex vivo costimulated autologous T-cells in conjunction with Pneumococcal conjugate vaccine immunization for patients with multiple myeloma"

Qing Chen, PhD
H. Lee Moffitt Cancer Center
"Involvement of fanconi anemia/BRCA DNA repair pathway in acquired melphalan drug-resistant myeloma cells"

Ebenezer David, PhD
Winship Cancer Center, Emory University
"Molecular mechanisms and synergy between proteasome inhibition and farnesyl transferase inhibition in multiple myeloma cells"

Irene Ghobrial, MD
Mayo Clinic
"Studies of the CXCR4/P13Kinase pathway in multiple myeloma"

Bao Hoang, PhD
UCLA West LA VA Medical Center
"Adhesion-mediated effects on mTOR in MM cells"

Irina Mazo, MD, PhD
Harvard Medical School
"Role of differential CD8 T cell therapies for mm"

Jennifer Lisa Bromberg-White, BA, PhD
Van Andel Research Institute
"Validation of melphalan-resistance targets in vitro in human mm cell lines utilizing a retroviral based RNAi delivery system"

Huajun Yan, PhD
West LA VA Medical Center
"Translational control of apoptosis in multiple myeloma: molecular mechanisms whereby mTOR inhibitors sensitize cells to apoptosis"

2004 Senior Research Award

Jaime Claudio, PhD
Toronto General Research Institute, University Health Network
"High throughout exon-scanning of the Kinome in multiple myeloma"
Awarded Second Year of Funding

Bjarne Bogen, MD, PhD
University of Oslo, Norway
"Vaccination against multiple myeloma with Vaccibodies from experimental immunology to patients"

Lung-Ji Chang, PhD
University of Florida
"Immunotherapy targeting multiple myeloma specific antigens"

Teru Hideshima, MD, PhD
Dana-Farber Cancer Institute
"Defining mechanisms of resistance to Velcade: clinical implication"
Awarded Second Year of Funding

Constantine Mitsiades, MD, PhD
Dana-Farber Cancer Institute
"Translational studies of IGFs/IGF-1R inhibition for the treatment of MM."
Awarded Second Year of Funding

Yu-Tzu Tai, PhD
Dana-Farber Cancer Institute
"Targeting CD40 therapy using humanized mAbs, alone or with IMiD3 in human MM"
Awarded Second Year of Funding

Huidong Shi, PhD
The Curators of the University of Missouri-Columbia
"Epigenetic Profiling in multiple myeloma"

Megan Sykes, MD
Massachusetts General Hospital
"Immunobiology of lymphohematopoietic GVH reactions"

Kelvin Lee, MD
University of Miami
"Targeting microenvironment pro-survival signals through CD28"

Dharminder Chauhan, JD, PhD
Dana-Farber Cancer Institute
"Targeting mitochondria to overcome conventional and Bortezomib/Proteasome Inhibitor PS-341 resistance in multiple myeloma cells"

Ramesh Batchu, PhD
University of Arkansas for Medical Science
"Prime-boost DNA/Adeno-associated viral (AAV) vaccine for multiple myeloma with MAGE A3-NY-ESO-1 fusion genes"

Derek Nigel John Hart, MB, ChB, DPhil
Mater Medical Research Institute
"Validation of potential myeloma target antigens for blood dendritic cell immunotherapy"

2004 Collaborative Program Grant

In October, the MMRF, the world's largest private funder of myeloma-specific research, proudly announced that a team of researchers from the Dana-Farber Cancer Institute is the recipient of its 2004 Collaborative Program Grant. The grant, which provides $1.5 million over a 3-year period, is designed to foster unique collaborations among researchers and institutions to help bring new therapies to the clinic quickly.

The Collaborative Program, titled Development of Molecularly-Based Combination Therapy for Multiple Myeloma, is led by Kenneth C. Anderson, MD, Kraft Family Professor of Medicine and the Director of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute. According to Dr. Anderson, the program consists of three closely-linked core projects that are centered on the common theme that the interaction between the myeloma cell and its microenvironment is important for tumor cell growth and survival, as well as the development of resistance to therapy.

Collaborative Grant: Program Interactions

  • Project 1 will use genomics to identify optimal combinations of novel agents and is led by principal investigators Ruben Carrasco, MD, PhD, Li Cheng, PhD, and Nikhil C. Munshi, MD. Agents to be evaluated include those that target the myeloma cell and its bone marrow microenvironment, drugs that target myeloma cells at the cell surface, and drugs that target the bone marrow microenvironment.
  • Combinations of novel agents identified in Project 1 will be evaluated in Project 2 for their impact on signaling mediating myeloma cell growth, survival, drug resistance, and apoptosis in the lab (see figure). Project 2 is led by Dr. Anderson, Dharminder Chauhan, PhD, and Teru Hideshima, MD, PhD.
  • Project 3 will confirm the efficacy of these combined therapies against human myeloma cells in mouse models of human myeloma. This project is led by Constantine Mitsiades, MD, PhD and Edie Toolen, PhD. The in vivo effects of combined therapies in Project 3 will also be correlated with in vitro data from Projects 1 and 2 to validate the scientific rationale for combining single agents.

    Collectively, these studies will provide the preclinical basis for designing Phase I collaborative clinical trials evaluating combinations of novel agents. "The grant offers an unprecedented opportunity to rationally combine active single novel agents to enhance cytotoxicity on one hand and overcome drug resistance on the other," notes Dr. Anderson. "We are now poised to investigate this strategy-which has helped cure childhood acute lymphocytic leukemia and adult testicular cancer-in myeloma."